UVA Cancer Center researchers lead acute myeloid leukemia (AML) discovery that could pave the way for improved treatments and patient outcomes.
Tag: acute myeloid leukemia
Targeting fusion proteins may provide an improved therapeutic approach for leukemia patients.
With acute myeloid leukemia classification overseen by 3 separate guidelines, Firas El Chaer, MD, is working to bring order to the chaos.
Thomas Loughran, MD, reveals the most intriguing clinical applications for his LGL and acute myeloid leukemias research.
UVA Cancer Center is growing its Stem Cell Transplant Program and pioneering new approaches to treat AML and other hematological malignancies.
With a recent $10 million NIH program project grant, UVA top minds are working to reveal the potential of nanotechnology to treat cancer. Get a breakdown of how these tiny particles enhance drug delivery and learn how UVA is putting them to use.